BioCentury This Week Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
22 snips
Mar 24, 2026 A two-decade company rebirth toward RNAi and a risky commercial launch that could reshape its trajectory. A $2 billion deal for a pan-mutant-selective PI3Kα inhibitor and what that means for strategic partnering. How AI is being woven into venture processes from deal screening to portfolio support. Advocacy clashes over rare-disease approvals and the political fight over most-favored-nation drug pricing.
AI Snips
Chapters
Transcript
Episode notes
Arrowhead's 20 Year Pivot To A TRiM RNAi Company
- Arrowhead transformed from a failing nanotech holding company into an RNAi-focused biotech by pivoting leadership and concentrating on RNAi after acquiring Caltech IP.
- A 2016 preclinical safety signal forced them to scrap clinical programs and rebuild on the TRiM subcutaneous siRNA platform, which now underpins their pipeline and strategy.
Redempla Is A Launch Pad For A Much Larger Triglyceride Market
- Redemplopliziran (APOC3-targeting) is Arrowhead's first commercial launch and a beachhead in FCS with potential expansion into severe hypertriglyceridemia affecting millions.
- Investors value the drug’s quarterly dosing, stronger FCS efficacy vs. Ionis' Tringolza, and upcoming phase 3 severe hypertriglyceridemia readout in Q3.
Beyond The Liver Delivery Is Central To Growth
- Arrowhead is pursuing delivery beyond the liver using adipose-targeted programs like ALK7, showing adipose mRNA knockdown in phase 1.
- They’re also developing bispecific ‘dimer’ siRNAs (PCSK9 + APOC3) and plan multiple dimer combinations for obesity.